Clinical Trials Directory

Trials / Not Yet Recruiting

Not Yet RecruitingNCT07525739

Assessing Changes in the Gut Microbiome of Non-Gastrointestinal Disordered Subjects Before and After Oral Prebiotic Supplementation Using the SIMBA Capsule

Status
Not Yet Recruiting
Phase
Phase 4
Study type
Interventional
Enrollment
30 (estimated)
Sponsor
Nimble Science Ltd. · Industry
Sex
Male
Age
19 Years – 40 Years
Healthy volunteers
Accepted

Summary

This is a randomized, double-blind, placebo-controlled, parallel-group clinical study. The primary objective is to assess the changes in the small intestinal (SI) metagenomic profile of healthy participants without any known gastrointestinal disorders from baseline to endpoint in response to the prebiotic intervention (FiberSmart). The study population are adults (n=30) who will ingest either the FiberSmart or a matched Placebo daily for 21 days. Both products will be referred to as the Investigational Product (IP) in the study procedures section. While prebiotics are widely used for gut health, their specific impact on the small intestinal ecosystem remains largely uncharacterized compared to the large intestine. Understanding their impact on the upper GI tract can lead to new insights into their mechanisms of action. Given the critical role of the small intestine in metabolism and immunity, the study utilizes the SIMBA capsule to measure novel changes in the small intestine along with traditional measurements from stool samples.

Conditions

Interventions

TypeNameDescription
DIETARY_SUPPLEMENTFiberSmartAnderson Global's FiberSmart Formulation, branded as FiberSmart, which is a soluble tapioca fiber powder (resistant dextrin). Natural Product Number 80091222. The product is a prebiotic supplement intended for oral consumption.
OTHERPlaceboPlacebo: Microcrystalline Cellulose, matches for appearance and taste, and is inert without prebiotic effects.

Timeline

Start date
2026-05-01
Primary completion
2026-08-01
Completion
2026-09-01
First posted
2026-04-13
Last updated
2026-04-13

Locations

1 site across 1 country: Canada

Source: ClinicalTrials.gov record NCT07525739. Inclusion in this directory is not an endorsement.